The UK’s Medicines and Healthcare products Regulatory Agency has signed off on a Phase 3 clinical trial evaluating CytoDyn’s (OTCQB:CYDY) leronlimab in severely ill and critically ill COVID-19 patients.
Yesterday, it requested Fast Track approval of the drug based on the results from a mid-stage study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.